RxDoctor Payments DataLook up a doctor →

Walter Duffy, MD

Psychiatry · Lincoln, NENPI 1093853368

Payments from drug & device makers

$7,354,334in general payments, 2019–2025

Across 2,647 payments — averaging $2778.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$2M
  • Sage Therapeutics, LLC$870K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$713K
  • Alkermes, Inc.$710K
  • AbbVie$572K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$446K
  • plus $2.1M from 41 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Livanova USA, Inc.547$1,986,233
Sage Therapeutics, LLC76$869,631
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)207$713,385
Alkermes, Inc.384$710,374
AbbVie(2 entities)264$571,964
Otsuka Pharmaceutical Development & Commercialization, Inc.16$446,331
Sanofi Pasteur Inc.13$328,975
Supernus Pharmaceuticals, Inc.142$328,831
Corium, LLC94$276,361
Merck11$257,461
Neurocrine Biosciences, Inc.155$226,218
Shire North American Group Inc31$128,884
Vanda Pharmaceuticals Inc.2$73,196
GSK37$67,706
Jazz Pharmaceuticals Inc.84$66,925
Takeda Pharmaceuticals U.S.A., Inc.58$42,022
Biohaven Pharmaceuticals, Inc.11$34,258
Collegium Pharmaceutical, Inc.7$34,151
Teva Pharmaceuticals USA, Inc.99$31,588
Corcept Therapeutics8$31,476
Acadia Pharmaceuticals Inc8$28,140
Janssen Research & Development, LLC4$26,733
Sumitomo Pharma America, Inc.35$23,438
F. Hoffmann-la Roche AG5$11,206
Sunovion Pharmaceuticals Inc.33$10,544
Ironshore Pharmaceuticals Inc.34$9,660
H. Lundbeck A S9$7,981
Biohaven Pharmaceutical Holding Company Ltd.6$7,010
Otsuka America Pharmaceutical, Inc.82$1,221
Axsome Therapeutics, Inc.56$613
Johnson & Johnson42$576
Harmony Biosciences LLC27$452
E.r. Squibb & Sons, L.L.C.24$237
Avanir Pharmaceuticals, Inc.8$106
Tris Pharma Inc7$102
Biogen3$64
Adlon Therapeutics L.p.3$45
Almatica Pharma LLC2$44
Bausch Health US, LLC2$41
Idorsia Pharmaceuticals US Inc3$38
Avadel CNS Pharmaceuticals, LLC2$29
Galderma Laboratories, L.p.1$18
Stryker1$17
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$15
Noven Therapeutics, LLC1$14
Lilly USA, LLC1$13
Janssen Scientific Affairs, LLC1$4

How this compares

$7,354,334 in reported general payments places this provider in the 95th percentile of 160 psychiatry providers in Nebraska.

See all psychiatry providers in Nebraska

Medicare billing

Part B allowed, 2024
$311,618
Medicare patients
292
Services billed
2,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →